© Reuters. Pharmamar rises 0.11% after drug approval in CanadaUpdate EC4106 with transaction closing details
Madrid, Sept. 30 (.) Treatment of lung cancer.
The pharmaceutical company, which had risen more than 2% at some point in the session, led the improvement of the key indicator of the national market, ending today at eight euros higher at 74.48 euros per share.
During the year of accumulation, its shares are revalued at 5.58%.
Legal warning: Fusion Media I would like to remind you that the data on this website is not real-time or accurate. All CFDs (stocks, indices, futures) and forex prices are not provided by exchanges but by market makers, so prices may be inaccurate and may differ from the actual market price, i.e. prices are indicative and not relevant for trading purposes. Therefore, Fusion Media will not be responsible for any business losses you may incur due to the use of this data.
Fusion Media No one associated with Fusion Media will be liable for any loss or damage as a result of relying on information on the Website, including buying / selling data, quotes, charts and signals. Please be fully informed about the risks and costs associated with financial market trading, which is one of the potentially risky investment forms.
More Stories
Acrylic or Gel? Key Differences to Help You Decide
Creating the Ideal Environment for Your Pet Tortoise
In Search of Adrenaline: What Kinds of Extreme Tourism to Try